• Revenues from Continuing Operations up 25% to $29,267k
• Net Loss from Continuing Operations after Tax up 3% to $9,059k
• Glaucoma Surgical Devices segment reported $29,077k in revenues

Nova Eye Medical Ltd has released its annual report for the financial year ended 30 June 2025. The company reported revenues from continuing operations of $29,267k, up 25% from the previous year. However, the net loss from continuing operations after tax increased by 3% to $9,059k. The Glaucoma Surgical Devices segment was the main contributor to revenues, reporting $29,077k in sales, up from $23,157k in the prior year. The AlphaRET segment, responsible for the commercialization of the 2RT® ophthalmic laser, did not generate material revenues during the year. The company faced several business risks, including foreign exchange rate volatility, supply chain disruptions, and regulatory compliance challenges. Looking ahead, the company will continue to focus on the further development of its ophthalmic devices business globally.